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Purpose or Objective  
There is a paucity of level one evidence and a limited 
number of institutional series guiding management of 
patients with head and neck squamous cell carcinoma and 
N3 nodal disease (N3 HNSCC). Thus, larger data sets are 
essential to generate robust data appropriate for directing 
patient care. 
The current study utilized the National Cancer Data Base 
(NCDB) to evaluate patterns of care and clinical outcomes 
for patients with N3 HNSCC. 
Material and Methods  
We performed a retrospective analysis of patients with N3 
HNSCC identified in the NCDB treated with either primary 
surgery followed by adjuvant therapy or primary 
chemoradiotherapy (CRT). Factors associated with 
treatment were analyzed with binary logistic and 
multivariate regression.  Multivariate (MVA) Cox 
proportional hazards analysis was utilized to determine 
factors correlated with overall survival. Kaplan-Meier 
curves with inverse probability of treatment-weighting 
were used for survival analysis.  
Results  
We identified 1,464 (30%) and 3,403 (70%) patients with 
N3 HNSCC treated with either primary surgery or CRT, 
respectively. Increasing age, non-private/unknown 
insurance, oropharyngeal or hypopharyngeal primaries, 
increasing tumor size, and higher T-stage were associated 
with CRT, whereas high-volume center, lower T-stage, 
oral cavity primary, and being diagnosed in more 
contemporary years were associated with surgery.  On Cox 
proportional MVA, increasing age, non-white race, non-
private/unknown insurance, increasing tumor size, T4 
stage, and CRT were associated with lower overall 
survival.  Propensity-adjusted median survival was 54.2 
and 44.8 months for surgery and CRT, respectively (p = 
0.0589).  In subgroup analysis, oropharyngeal primary 
subsite gained a survival advantage with surgery versus 
CRT with median survivals of 86.0 and 61.9 months, 
respectively (p = 0.0153).    
Conclusion  
The majority of N3 HNSCC patients receive primary 
CRT.  After adjustment for factors influencing treatment 
approach, patients treated with surgery and CRT exhibit 
similar survival outcomes with 5-year overall survival 
approaching 30-50% depending on the primary tumor 
subsite.  Patients with oropharynx primaries benefit from 
primary surgical approach in terms of overall survival. 
Those with oropharynx HPV-positive tumors represent a 
favorable subset of N3 HNSCC patients.   These data 
represent the most comprehensive analysis of N3 HNSCC 
outcomes and serve as a foundation to guide clinical 
management, as well as future research endeavors. 
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Purpose or Objective  
To evaluate the results of sentinel lymph node biopsy 
(SLNB) in patients diagnosed with a T1-T2 oral squamous 
cell carcinoma and clinically negative (N0) neck in two 
Dutch Head and Neck centers. 
Material and Methods  
Retrospective analysis of 226 previously untreated 
patients, who underwent SLNB between 2007 and 2016. 
The SLNB procedure consisted of preoperatively 
performed lymphoscintigraphy, intraoperative detection 
using blue dye and/or gamma probe guidance and 
histopathological examination including step-serial 
sectioning and immunohistochemical stainings. A positive 
SLNB was followed by a neck dissection, while regular 
follow-up with ultrasound guided fine-needle aspiration 
cytology was followed in case of a negative SLNB. 
Results  
The identification rate was 97% (220/226). At least one 
histopathologically positive SLN was found in 52 of 220 
patients (24%). Sensitivity of SLNB was 83% and the 
negative predictive value was 93%. Patients with a floor of 
mouth tumor showed a lower sensitivity (67% vs. 88%, 
P=0.11) and negative predictive value (90% vs. 95%, 
P=0.31) compared with patients with other tumor 
locations. Median follow-up was 22 months (1-104). 
Overall survival, disease-specific survival and disease-free 
survival for SLN negative and SLN positive patients were 
77%, 90% and 99% vs. 73%, 86% and 87%. 
Conclusion  
SLNB is a safe and reliable diagnostic staging technique for 
detection of occult lymph node metastasis in patients with 
early stage (T1-T2, cN0) oral cavity squamous cell 
carcinoma, but needs improvement in patient with floor 
of mouth tumors. 
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Purpose or Objective  
Due to lifestyle factors head and neck cancer patients 
have a high risk of having metastatic disease or a 
synchronous cancer at the time of diagnosis. Malignancy 
diagnosed outside the head and neck region can have a 
profound effect on the clinical approach. At our institution 
patients referred for curative radiotherapy have been 
routinely planned with whole-body PET-CT. To determine 
the incidence of malignant disease outside the head and 
neck region we examined the planning PET-CT scans of 
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Material and Methods  
All patients with SCCHN planned for radiotherapy with 
curative intent who underwent a whole-body planning 
PET/CT scan from 2006 – 2012 were eligible. A radiologist 
and a nuclear medicine physician prospectively evaluated 
all scans. Any suspicious lesions outside the head and neck 
region were noted. Using patient files, pathology registers 
and other clinical systems all eligible patients were 
retrospectively investigated and evaluated for malignant 
disease. Confirmation of malignancy, either disseminated 
SCCHN or a synchronous secondary cancer was done by 
histological verification or by follow-up imaging. 
Results  
A total of 1110 patients with primary SCCHN were eligible. 
Pathological lesions outside of the head and neck region 
were described in 326 (29%) patients, with 158 patients 
having lesions suspicious of malignancy, whereas lesions 
on 168 patients were deemed benign. In total, malignancy 
was diagnosed in 92 (8.2%) patients of which 56 (61%) was 
confirmed histological. The malignant lesions comprised 
48 patients (4.3%) with metastatic SCCHN, 38 (3.4%) 
patients with a synchronous cancer, and 6 (0.5%) patients 
with malignancy of unknown origin. Lung cancer (n=24) 
was the predominant synchronous cancer. Forty-two 
patients with pathological lesions outside the head and 
neck were unresolved due to death within 6 months of 
diagnosis (n=27), lost to follow-up (n=11) or refused 
further diagnostic evaluation (n=4). Of the 158 patients 
with lesions suspicious of malignancy, 76 (48%) patients 
had a malignant lesion confirmed, whereas it was rejected 
in 61 (39%) patients. In the 168 patients with lesions 
deemed benign by PET/CT a malignant lesion was later 
confirmed in 16 (10%) patients. 
Conclusion  
Patients with primary SCCHN have a substantial risk of 
malignant disease outside the head and neck region, which 
may influence the overall treatment strategy. A PET/CT 
scan before onset of radiotherapy is clinically useful in 
identifying these patients. However, a significant 
proportion of lesions described as suspicious of malignancy 
were in fact benign. 
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Purpose or Objective  
Disease recurrence is an important clinical endpoint in 
head and neck cancer and we therefore validated a 
prognostic model on this endpoint with p16 negative (p16-
) and p16 positive (p16+) neck squamous cell carcinoma 
(HNSCC). In addition, we compared the performance of 
the validated model with the proposed ICON-S staging for 
patients with p16+ oropharyngeal SCC (OPSCC)[1] and with 
UICC staging for other HNSCC. 
[1] O’Sullivan B et al. Lancet Oncol 2016 
Material and Methods  
Consecutive patients with HNSCC (excluding 
nasopharyngeal carcinomas) and a pre-treatment FDG 
PET/CT treated with curative intent IMRT at a single 
institution from 2005 – 2012 were included. The cohort 
was divided into 3 groups: Training set (p16- OPSCC and 
non-OPSCC patients treated from 2005 – October 2009), 
Validation set 1 (p16- OPSCC and non-OPSCC patients 
treated from October 2009 – 2012) and Validation set 2 
(p16+ OPSCC patients treated from October 2005-2012). 
We have previously developed and published a prognostic 
model including four significant variables (treatment with 
Cisplatin, smoking status, FDG uptake and tumor size; the 
latter two as continuous variables) in the training set. The 
prognostic model was used to generate four risk groups 
based on the predicted risk of disease recurrence after 2 
years (Intervals 0-10%; 10-30%; 30-60% and >60%). Here, 
we test the prognostic model on the two validation sets. 
The performance of the original model was compared with 
the UICC staging for validation set 1 and with ICON-S 
staging for validation set 2. The performance was assessed 
with concordance index (CI) where a CI=1 corresponds to 
ideal prognostication and CI=0.5 corresponds to a coin 
toss. 
Results  
A total of 600 patients were included. The training set 
included 168 patients, validation set 1 included 224 
patients and validation set 2 included 183 patients (p16 
status could not be performed in 25 patients).Figures 1a 
and 1b depict the Kaplan-Meier (KM) curves of freedom 
from failure (FFF) in validation set 1 using the prognostic 
model developed from the training set (1a) and the UICC 
staging (1b).The prognostic model provides better 
distinction of patients than the UICC stating system in 
validation set 1. The CI for UICC staging is 0.63 compared 
to 0.74 for our validation (p=0.03; table 1). Figures 1c and 
1d depict the KM curves of FFF for patients in validation 
set 2 using the prognostic model developed from the 
training set (1c) and ICON-S (1d). The distinction between 
patients is not obviously better with the prognostic model. 
The CI is slightly better with our prognostication (table 1), 




This is a validation of a previously suggested prognostic 
model. The validated model provides a better 
prognostication of risk of disease recurrence than UICC 
